Bull Flag Stocks
KOD is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
KODIAK SCIENCES INC (KOD) Stock Price & Overview
NASDAQ:KOD • US50015M1099
Current stock price
43.96 USD
+0.48 (+1.1%)
At close:
43.96 USD
0 (0%)
After Hours:
The current stock price of KOD is 43.96 USD. Today KOD is up by 1.1%. In the past month the price increased by 8.2%. In the past year, price increased by 815.83%.
KOD Key Statistics
52-Week Range2.8101 - 47.8417
Current KOD stock price positioned within its 52-week range.
1-Month Range38.37 - 47.8417
Current KOD stock price positioned within its 1-month range.
- Market Cap
- 2.719B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.32
- Dividend Yield
- N/A
KOD Stock Performance
Today
+1.1%
1 Week
-1.96%
1 Month
+8.20%
3 Months
+93.06%
Longer-term
6 Months +142.54%
1 Year +815.83%
2 Years +1,282.39%
3 Years +641.31%
5 Years -47.43%
10 Years N/A
KOD Stock Chart
KOD Stock Screens
KOD currently appears in the following ChartMill screener lists.
KOD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KOD. When comparing the yearly performance of all stocks, KOD is one of the better performing stocks in the market, outperforming 99.54% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
KOD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KOD. The financial health of KOD is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
KOD Earnings
Next Earnings DateMay 20, 2026
Last Earnings DateMar 27, 2026
PeriodQ4 / 2025
EPS Reported-$1.04
Revenue Reported
EPS Surprise 2.24%
Revenue Surprise %
KOD Forecast & Estimates
11 analysts have analysed KOD and the average price target is 56.71 USD. This implies a price increase of 29.01% is expected in the next year compared to the current price of 43.96.
Analysts
Analysts80
Price Target56.71 (29%)
EPS Next Y13.54%
Revenue Next YearN/A
KOD Index Membership
KOD is currently included in the following stock indexes tracked on ChartMill.
KOD Financial Highlights
Over the last trailing twelve months KOD reported a non-GAAP Earnings per Share(EPS) of -4.32. The EPS decreased by -28.57% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-229.97M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.42% | ||
| ROE | -146.12% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-23.81%
Sales Q2Q%N/A
EPS 1Y (TTM)-28.57%
Revenue 1Y (TTM)N/A
KOD Ownership
Ownership
Inst Owners89.11%
Shares61.85M
Float57.78M
Ins Owners5.2%
Short Float %17.86%
Short Ratio8.69
KOD Industry Overview
KOD operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
KOD Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KOD
Company Profile
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 123 full-time employees. The company went IPO on 2018-10-04. The firm has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. The company is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Company Info
IPO: 2018-10-04
KODIAK SCIENCES INC
1250 Page Mill Rd
Palo Alto CALIFORNIA 94304 US
CEO: Victor Perlroth
Employees: 124
Phone: 13026365400
KODIAK SCIENCES INC / KOD FAQ
What does KODIAK SCIENCES INC do?
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 123 full-time employees. The company went IPO on 2018-10-04. The firm has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. The company is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
What is the stock price of KODIAK SCIENCES INC today?
The current stock price of KOD is 43.96 USD. The price increased by 1.1% in the last trading session.
Does KODIAK SCIENCES INC pay dividends?
KOD does not pay a dividend.
What is the ChartMill technical and fundamental rating of KOD stock?
KOD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is KODIAK SCIENCES INC worth?
KODIAK SCIENCES INC (KOD) has a market capitalization of 2.72B USD. This makes KOD a Mid Cap stock.
Can you provide the short interest for KOD stock?
The outstanding short interest for KODIAK SCIENCES INC (KOD) is 17.86% of its float.